Related Experiment Video

Updated: Aug 16, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Complexities in the development of cyclin-dependent kinase inhibitor drugs

Edward A Sausville1

  • 1Developmental Therapeutics Program, National Cancer Institute, Executive Plaza North Room 8018, 6130 Executive Boulevard, Rockville, MD 20852, USA. sausville@nih.gov

Trends in Molecular Medicine
|April 3, 2002
PubMed

Insights

Cyclin-dependent kinases (CDKs) are key regulators of the cell cycle and are implicated in cancer. New research explores novel CDK targets beyond cell cycle control, including transcription and cell function, for therapeutic strategies.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Oncology

Background:

  • Cell cycle regulation is critical for preventing uncontrolled cell proliferation, a hallmark of neoplasia.
  • Cyclin-dependent kinases (CDKs) are central regulators of the cell cycle.
  • Dysregulation of cell cycle control is a fundamental defect in tumor development.

Purpose of the Study:

  • To explore the role of cyclin-dependent kinases (CDKs) in neoplasia.
  • To investigate novel CDK family members influencing transcription and cell function.
  • To identify new therapeutic strategies targeting CDKs in cancer.

Main Methods:

  • Review of recent advances in synthetic chemistry for CDK inhibitor development.
  • Analysis of emerging research on non-cell cycle regulatory CDK functions (e.g., CDK7, CDK8, CDK9, CDK5).
  • Exploration of therapeutic strategies targeting transcription control and other CDK-related pathways.

Main Results:

  • Identification of CDK family members with roles beyond direct cell cycle regulation, impacting transcription and cellular functions.
  • Development of novel selective inhibitors for various CDKs.
  • Emerging strategies for targeting CDK-related pathways, including transcription control.

Conclusions:

  • CDKs represent important and underexplored targets for cancer therapy.
  • Understanding the complex cellular physiology of CDKs is crucial for developing effective treatments.
  • Targeting novel CDK functions offers promising avenues for future cancer drug development.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...